EN DE
STOCK COMPARISON

Helius Medical Technologies Inc Class A vs Fondul Proprietatea: Fair Value & Quality

Both stocks run through our valuation models. Here is how Helius Medical Technologies Inc Class A (HSDT) and Fondul Proprietatea (FP) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Fondul Proprietatea as the less overvalued of the two: Helius Medical Technologies Inc Class A trades at $1.69 versus a fair value of $0.41 (-76%), while Fondul Proprietatea trades at 0.61 versus 0.21 (-66%).
Helius Medical Technologies Inc Class A
HSDT · USD · Health Care
-76%
upside to fair value
overvalued
Price$1.69
Fair Value$0.41
Quality27/100
Fondul Proprietatea
FP.RO · Financials
-66%
upside to fair value
overvalued
Price0.61
Fair Value0.21
Quality92/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Helius Medical Technologies Inc Class AFondul Proprietatea
Valuation
0.0×P/E (TTM)4.3×
9.86×P/S (TTM)0.81×
0.31×P/B0.17×
Dividend yield6.9%
Dividend per share0.04
Profitability
0%Net margin92%
-137%Return on equity20%
Return on assets11%
Growth
7290%Revenue growth (YoY)524%
97.0%Avg. growth/yr (3Y)-45.0%
55.5%Avg. growth/yr (5Y)
Balance & size
$95MMarket cap$387M
mixedGrowth qualityweak

Fondul Proprietatea leads: 3 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Helius Medical Technologies Inc Class Aof which business quality 27 · market factors 13 Fondul Proprietateaof which business quality 87 · market factors 80
ProfitabilityMargins and returns on capital today
1
67
Quality GrowthAre margins and returns improving?
80
95
CashflowEarnings quality: real cash, not paper profit
0
100
Fin. StrengthBalance sheet, leverage, solvency risk
77
73
InvestmentDisciplined investing over empire-building
0
100
Low VolatilityCalm price path (market factor)
30
87
MomentumPrice trend over the last 3–12 months (market factor)
8
71
52W MomentumDistance to the 52-week high (market factor)
1
86
Net IssuanceBuybacks instead of dilution
0
100

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Helius Medical Technologies Inc Class A

Multiples$4.38
Asset-Based$3.45

0 of 2 models see the stock below the current price.

Fondul Proprietatea

DCF Models2.74
Earnings-Based6.29
Multiples1.55
Asset-Based0.53
Growth DCF0.84
Economic Profit1.26

1 of 10 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Helius Medical Technologies Inc Class A
Bear $0.27Fair Value $0.41Bull $0.51
$1.69 = current price (white tick)
Fondul Proprietatea
Bear 0.16Fair Value 0.21Bull 0.27
0.61 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Helius Medical Technologies Inc Class A · Health Care

Quality score27 · bottom 25%
Fair value upside-76% · bottom 25%

Fondul Proprietatea · Financials

Quality score92 · Top 25%
Fair value upside-66% · bottom 25%

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Fondul Proprietatea as the less overvalued of the two: Helius Medical Technologies Inc Class A trades at $1.69 versus a fair value of $0.41 (-76%), while Fondul Proprietatea trades at 0.61 versus 0.21 (-66%).

Fondul Proprietatea has the higher quality score (92/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.